Please use this identifier to cite or link to this item:
Title: Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia
Authors: Lima, Luciene Terezina de
Vivona, Douglas
Bueno, Carolina Tosin
Hirata, Rosario D. C.
Hirata, Mario H.
Luchessi, Andre D.
Castro, Fabiola Attie de
Chauffaille, Maria de Lourdes F. [UNIFESP]
Zanichelli, Maria A.
Chiattone, Carlos S.
Hungria, Vania Tietsche de Moraes
Guerra-Shinohara, Elvira M.
Universidade de São Paulo (USP)
Universidade Federal de São Paulo (UNIFESP)
Hosp Brigadeiro
Keywords: Imatinib mesylate
Chronic myeloid leukemia
Membrane transporter
Issue Date: 1-Mar-2014
Publisher: Humana Press Inc
Citation: Medical Oncology. Totowa: Humana Press Inc, v. 31, n. 3, 11 p., 2014.
Abstract: Imatinib mesylate (IM) has become a standard of care in chronic myeloid leukemia (CML) therapy. Single nucleotide polymorphisms (SNPs) and altered expression in drug transporter genes may influence IMresponse. in order to investigate whether mRNA expression and SNPs in drug transporters are associated with IM resistance, we studied 118 chronic-phase CML patients receiving the standard dose of IM (400 mg/day). They were assigned as responders and non-responders according to European Leukemia Net criteria (2009). mRNA expression in samples at diagnosis (without IM therapy) and outcomes after IM failure were also evaluated in subgroups of patients. Major molecular response (MMR), complete molecular response and primary and secondary resistance were all assessed. BCR-ABL1, ABCB1, ABCG2, SLC22A1 and SLCO1A2 mRNA expression and SNPs in ABCG2 and SLC22A1 genes were analyzed. ABCG2 mRNA expression in the non-responders was higher before and during IM therapy. Furthermore, ABCG2 was overexpressed in those who did not achieve MMR (P = 0.027). in a subgroup of patients who switched to second-generation tyrosine kinase inhibitors, high mRNA expression of ABCG2 was associated with a risk of 24 times that of not achieving complete cytogenetic response (OR 24.00, 95 % CI 1.74-330.80; P = 0.018). in the responder group, patients who achieved MMR (P = 0.009) presented higher mRNA levels of SLC22A1. the SNPs were not associated with mRNA expression of ABCG2 and SLC22A1. Our data suggest that elevated ABCG2 expression (an efflux transporter) could be associated with IM resistance and could impact on second-generation TKI response, whereas high SLC22A1 expression (an influx transporter) may be associated with a successful IM therapy in CML patients.
ISSN: 1357-0560
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.